For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health ...

This year has seen a rapid rise in the demand for Ozempic due to it being popularised by celebrity endorsements online, leading to a shortage of product. Ozempic is a brand of semaglutide that helps ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...